Abzena Group

Abzena plc is a life sciences company providing services and technologies. The Company is engaged in the provision of services and technology licenses. The Company consists of PolyTherics and Antitope, which have established a suite of services and technologies that are designed to improve the chances of development of antibodies and proteins with therapeutic benefits. Antitope provides immunogenicity assessment, protein engineering and manufacturing cell line development. The Company's protein engineering technologies, Composite Human Antibodies and Composite Proteins, are used to create products with less risk of producing an unwanted immune response in patients. PolyTherics specializes in site-specific bioconjugation of drugs to therapeutic antibodies and other targeting proteins, which deliver the drug to specific cells, including cancer cells.
Company Type
Twitter Account
@AbzenaGroup

Arcinova

Arcinova is a Contract Research and Development Organisation (CRDO), providing the pharmaceutical industry with a comprehensive range of services.

At Arcinova, we are focused on Process, Research, Development, Scale-Up and small scale manufacturing, including bioanalysis, DMPK, regulatory and consulting services, covering drug candidates in Development and launched to the Market.

Company Type
Twitter Account
#Arcinova

Domainex Ltd

Domainex is a drug discovery company with a reputation for speed and innovation built on an exceptional track record of drug candidate delivery. It has a world class discovery team with an unrivalled track record and three client drug candidates.
Company Type
Twitter Account
@Domainex_UK

Fusion Antibodies

Fusion Antibodies is a CMO that offers a range of services covering all stages of therapeutic and diagnostic antibody development from target discovery to delivery of lead optimized commercial candidates suitable for cGMP scale up.

Fusion provides contract services include...

- Antibody Humanization services
- Antibody Engineering Services
- Antibody sequencing Services
- Protein Expression & Purification Services
- Monoclonal Antibody services BLAST & Standard
- cGMP Services

Company Type
Twitter Account
@FsnAntibodies

Imanova

Imanova has world-leading expertise in imaging sciences and their application to the understanding of disease and translational drug development. An innovative joint venture, Imanova’s shareholders are the UK's Medical Research Council and three world-class London universities: Imperial College London, King’s College London and University College London.

Imanova is a company with a depth of understanding in drug development and extensive experience using imaging to facilitate the development pipeline. Our academic expertise and extensive links with clinicians and scientists in our shareholder institutions provide unrivalled capabilities to facilitate drug development.

Company Type
Twitter Account
@ImanovaImaging

Mironid

Mironid Limited is an innovative new drug discovery company that develops proprietary drug candidate molecules by modulating the activity of key cell signalling proteins. This allows us to access multiple therapeutic areas for exploitation. Our current drug discovery pipeline is aimed at developing novel treatments for degenerative kidney diseases, chronic inflammatory diseases and cancer.

Company Type
Twitter Account
@mironidltd

Oxstem

OxStem is a drug discovery company, spun-out from the University of Oxford, with the unique vision of developing in-situ cell programming therapies to treat what are typically (but certainly not exclusively) age-related conditions, such as Dementia, Heart Failure, Macular Degeneration (the leading cause of blindness in the developed world), Diabetes and Oncology.

The idea is straightforward - to use the Stem Cell and Medicinal Chemistry expertise within Chemistry and its associated partners at Oxford to identify new classes of drugs that can re-program or stimulate existing endogenous cells - awakening previously defunct or dormant cellular processes.

Company Type
Twitter Account
@OxStem

PCI Pharma Services

PCI is a leading provider of integrated pharmaceutical development services to the global healthcare market. With facilities in North America and Europe, PCI supports pharmaceutical and biotech companies with products destined for more than 100 countries around the world. PCI provides services for each stage of the product lifecycle - from early Phase I through commercial launch and long-term supply - and partners with customers to provide key insight and expertise in enabling successful commercialization and bringing lifesaving medications to patients.

Sareum

Sareum is a drug discovery and development company, headquartered in Cambridge UK, that produces targeted small molecule therapeutics, focusing on cancer and autoimmune disease. Sareum aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.

Sareum operates an outsourced research model, working with collaborators (SRI International, the CRT Pioneer Fund and Hebei Medical University Biomedical Engineering Center) and a world-wide network of research providers. Its research pipeline includes two programmes undergoing pre-clinical IND-enabling studies.

SYNthesis Med Chem

SYNthesis med chem, founded in 2007, is a relatively new player in the chemistry CRO market. We are Australian owned with laboratory facilities in Shanghai China and offices in Australia, the US and the UK. The management team at SYNthesis are experienced drug discovery professionals with expertise across a range of targets (particularly Kinases, GPCRs and epigenetic targets).

Our clients are drawn from biotech, big pharma and academia, we have an outstanding client return rate with several clients working with us across two or more target classes.